

The aging CF patient - challenges for the clinical pharmacist

Adi Mester, MSc, MHA, BPharm

Pharmacist, CF Foundation of Israel





Clinical case 1 – Introduction

- MV, a 56 Year old patient
- Diagnosed during childhood as asthmatic
- The father of 2 daughters with CF
- CF was diagnosed in 2006 (age of 47)
- G542X / 5T
- Pancreatic sufficient
- 1.88 m, 103 kg (BMI = 29 kg / m²)
- Latest FEV₁ – 77%

MV – Problem list

- ABPA (Allergic broncho-pulmonary aspergillosis)
- Recurrent sinusitis
- GERD (gastro-esophageal reflux disease)
- Dyslipidemia
- Anxiety
- During the last year: pneumothorax, renal failure
- Latest HbA1c – 6.2%

MV - Chronic medications

1. Inh. Sol. Sodium chloride 6% (Mucoclear) - 4ml x 2 / day
2. Amp. Colistin (Coliracin) 1 million units (inhaled) x 2 / day
3. Cap omeprazole (Omepradex) 40 mg - 1 x 1 / day
4. Inh. Beclomethasone 100 microgram (Qvar) - 2 x 2 / day
5. Inh. Pwd. Formoterol / beclomethasone (Symbicort) 160 / 4.5 - 1 x 2 / day
6. Inh. Salbutamol (Ventolin) 100 microgram – SOS
7. Tab Rosuvastatin (Stator) 40 mg – 1 x 1 / day
8. Tab escitalopram (Cipralext) 10 mg – 1 x 1 / day

- November 2014 - Referred to the Clinic with an exacerbation, associated with his ABPA
- **What would you prescribe him?**
- Prednisone (40 mg / day for 3 day & tapering down)










MV - Treatment

- January 2015 – clinical worsening with a lot of coughs and chest pain. FEV₁ declined to 38%
- 107 kg (BMI – 30 kg / m²)
- Diet
- Pulse steroids (methyl prednisolone 1 gr / day x 3 days)
- Voriconazole 200 mg x 2 day

- ECG – normal sinus rhythm
- Tapering down SSRI



Drug-Drug Interactions (9)

Drugs:	Severity:	Documentation:	Summary:
CIPROFLOXACIN -- ESCITALOPRAM OXALATE	 Major	Fair	Concurrent use of ESCITALOPRAM and QT INTERVAL-PROLONGING DRUGS may result in increased risk of QT-interval prolongation.
CIPROFLOXACIN -- VORICONAZOLE	 Major	Fair	Concurrent use of CIPROFLOXACIN and VORICONAZOLE may result in an increased risk of QT interval prolongation.
ESCITALOPRAM OXALATE -- FORMOTEROL FUMARATE	 Major	Fair	Concurrent use of ESCITALOPRAM and QT INTERVAL-PROLONGING DRUGS may result in increased risk of QT-interval prolongation.
ESCITALOPRAM OXALATE -- VORICONAZOLE	 Major	Fair	Concurrent use of ESCITALOPRAM and QT INTERVAL-PROLONGING DRUGS may result in increased risk of QT-interval prolongation.
ALBUTEROL -- FORMOTEROL FUMARATE	 Moderate	Fair	Concurrent use of ALBUTEROL and ADRENERGIC AGONISTS may result in increased risk of adverse cardiovascular effects.
CIPROFLOXACIN -- PREDNISOLONE	 Moderate	Excellent	Concurrent use of SELECTED FLUOROQUINOLONES and SELECTED CORTICOSTEROIDS may result in an increased risk for tendon rupture.
CIPROFLOXACIN -- PREDNISONE	 Moderate	Excellent	Concurrent use of SELECTED FLUOROQUINOLONES and SELECTED CORTICOSTEROIDS may result in an increased risk for tendon rupture.
OMEPRAZOLE -- VORICONAZOLE	 Moderate	Excellent	Concurrent use of OMEPRAZOLE and VORICONAZOLE may result in increased plasma concentrations of omeprazole.
SULFAMETHOXAZOLE/ TRIMETHOPRIM -- VORICONAZOLE	 Moderate	Fair	Concurrent use of SULFAMETHOXAZOLE and CYP2C9

MV - Treatment

- **February** - clinical improvement, with FEV₁ returning almost to baseline (72%)
- Redness in the face
- ECG: QT elevation, within the norm
- SSRI was stopped
- **March** - clinical deterioration, with FEV₁ decline to 54%,
- Blushing, feeling of fever
- Voriconazole switched to itraconazole 200 mg x 2 / day

MV - Treatment

- April - hemoptysis
- Tranexamic acid, Ciprofloxacin, TMP/ SMX, prednisone
- May - clinically better, FEV₁ 64%
- Tapering down of steroids, Tranexamic acid stopped
- July - fever, muscle pains, light headedness
- Pulse steroids reduced to 800 mg x 1 / day
- Tingling in hands
- Switched itraconazole with amphotericin B inhalations


MV - Treatment

- August – FEV₁ = 75%
- ABPA is still active
- Diabetes, overweight
- Option - omalizumab as steroid sparing
- Anxiety

- October – FEV₁ = 81%
- No oral steroids or antibiotics


תאריך בדיקה	מדבקה	תוצאה	יחידת מידה	ערכי ייחוס	תוצאה גרפית
30/09/2015 09:16	227795	126 ↑	IU/ml	0-100	
09/08/2015 09:27	223858	213 ↑	IU/ml	0-100	
22/07/2015 14:37	222085	324 ↑	IU/ml	0-100	
19/04/2015 14:31	211943	648 ↑	IU/ml	0-100	
13/04/2015 11:39	211159	686 ↑	IU/ml	0-100	
25/03/2015 13:33	209667	468 ↑	IU/ml	0-100	
22/02/2015 09:29	206099	729 ↑	IU/ml	0-100	
21/01/2015 13:09	202496	1260 ↑	IU/ml	0-100	
27/11/2014 09:04	235978	1170 ↑	IU/ml	0-100	
07/08/2014 09:14	224955	428 ↑	IU/ml	0-100	
24/09/2013 10:00	229268	335 ↑	IU/ml	0-100	
14/07/2013 09:22	221677	369 ↑	IU/ml	0-100	
02/08/2012 08:06	222282	315 ↑	IU/ml	0-100	
10/10/2011 00:00	224441	564 ↑	IU/ml	0-100	

CF - from a childhood disease to a chronic condition



N.J. Simmonds: Ageing in Cystic Fibrosis and Long-term Survival. Paediatric Respiratory Reviews 14S (2013) 6-9

A demographic change in the proportion of patients over 18



N.J. Simmonds: Ageing in Cystic Fibrosis and Long-term Survival. Paediatric Respiratory Reviews 14S (2013) 6–9

Age and the Israeli CF population

- 572 CF patients are registered in Israel
- Average age: 22.94 years
- 361 (63.11%) are over 18 years old
- 58 (10.13%) are over 40 years old
- 34 (58.62%) are treated in Safra & Schneider's CF centers


Method

Included: All patients over 40 years
visited Safra / Schneider's CF centers
Excluded: lung transplant / death / lost
of follow up

Medical records reviewed for:

- Mutations
- Age of diagnosis
- Pancreatic in/ sufficiency
- Diabetes
- Osteopenia / osteoporosis
- BMI
- Latest FEV₁
- Pathogens
- No. of chronic medications
- Other medical conditions
- Parenting

- n = 29





Medical issues in the aging CF population

- The improvement in survival brings the potential for a new set of medical and psychosocial issues
- Broadly, these can be considered as CFTR or non-CFTR related

Medical issues in the aging CF population - CFTR-related


- Longevity exposes organs to abnormal CFTR function for a longer duration
- Susceptible tissues might eventually develop a disease, manifested as new symptoms





Average age: 50.67 years
Average FEV₁: 70.24%


Med age: 50 years
Med FEV₁: 72%




Average age PS: 53.28 years
Average age PI: 47.73 years

Average FEV₁ PS: 73%
Average FEV₁ PI: 67.66%


FEV1 and aging by mutation type



Parameters by mutation type




Parameters by gender




CFTR-related medical issues - Diabetes

- Has an age-dependent prevalence
- Associated with a decline in pulmonary function & nutrition
- An increase in *Pseudomonas aeruginosa* & *Burkholderia cepacia* infections
- Increase in hospitalizations rate



CFTR-related medical issues - Diabetes

- 9 patients (31%) of patients in Safra & Schneider are diagnosed with CFRDM




N.J. Simmonds: Ageing in Cystic Fibrosis
and Long-term Survival. Paediatric
Respiratory Reviews 14S (2013) 6-9

CFTR-related medical issues – Bone disease

- Bone mineral content (BMC) and bone mineral density (BMD) are usually normal in children with normal nutritional status and well preserved lung function
- Reduced BMD is common in adolescents and adults
- Adults have an increased risk of fracture compared to a healthy population of the same age and gender


Bone disease – Risk factors

- Poor nutritional status
- Reduced levels of weight bearing activity
- Effect of CFTR dysfunction on bone cells
- A negative calcium balance
- Abnormal fatty acid status
- Glucocorticoid treatment
- Lung infection
- Vitamin D insufficiency
- Vitamin K insufficiency
- Hypogonadism
- Delayed puberty
- CF related diabetes



Medical issues in the aging CF population - CFTR-related

- Other CFTR-related age-associated conditions include:
- Arthropathy
- Large volume haemoptysis
- Pneumothoraces
- Chronic *Pseudomonas aeruginosa* colonization



N.J. Simmonds: Ageing in Cystic Fibrosis and Long-term Survival. Paediatric Respiratory Reviews 14S (2013) 6–9

Medical issues in the aging CF population – non CFTR-related

- Non-CFTR-related Age-related complications of the general population
- intensifies the already burdensome treatment regimen
- Increasing the potential for drug-related interactions
- Historically, risk of cardiovascular disease had been estimated as very low in CF
- But, cases of myocardial infarction in pancreatic insufficient patients have been reported

Medical issues in the aging CF population – non CFTR-related

- Drug-related side effects are another important issue, as patients with CF live longer
- Aminoglycosides are used as anti bacterials and are instrumental in controlling disease
- Unfortunately, they might increase the incidence of renal and vestibulocochlear complications
- A large US registry study has reported of a three times elevated risk of gastro-intestinal tract cancers in CF
- The psychological stresses of living with a chronic condition
- Depression and other mental health issues often increase in adulthood
- Presumably, this might be due to increasing co-morbidities and personal responsibilities

Thanks

- Prof. Hannah Blau & the team of the Graub CF center, Schneider children's medical center of Israel
- Prof. Ori Efrati & the team of the national CF center, Edmond and Lily Safra children's hospital, Chaim Sheba medical center, Tel Ha'Shomer
- Dr. Vardit Kalamaro, Merav Meir & the CF foundation of Israel

